Calciscon AG (Switzerland) is the pioneering company in Calcification Propensity diagnostics, an unmet medical need with a market value estimated at CHF 1.5B (US$ 1.5B). The proceeds of its CHF 600k (US$ 650k) pre-series A financing enables the company to initiate initial sales of its flagship product the T50 Calcification Propensity test, while preparing for series A financing. Calciscon’s pre-series A financing was raised from the lead seed investors, and includes new strategic investors from the pharmaceutical and medical laboratory sectors. The total, cumulated equity investment in Calciscon is now CHF 2.5M (US$ 2.7M).
The company commercializes the T50 test, a patented IVD blood test for patients with chronic kidney disease (CKD). CKD affect 9% of the world population, and most CKD patients still suffer and die from cardiovascular (CV) disease with no notable outcome improvements in the last decades.
The T50 Calcification Propensity test is the first IVD test to functionally assess the tendency to calcify, revealing critical, previously unavailable information about CV risks to improve the therapy of patients. “The T50 is the long-awaited metric that provides a simple, yet complete, assessment of the calcification system” explains PD Dr. Andreas Pasch inventor of the T50 and founder of Calciscon, “allowing personalized therapeutic intervention in the patient to slow down disease progression”. Extensive clinical evidence demonstrates the T50 is a novel independent risk factor for both CV events and death.
The T50 is currently offered in Switzerland, and Calciscon will extend its availability to neighboring countries in the near term. “We are now giving nephrologists the opportunity to join our early access program to offer this breakthrough clinical tool to their patients” explains Vincent Linder Ph.D., CEO.